Aequus Pharmaceuticals Inc.

Equities

AQS

CA0076361033

Pharmaceuticals

Delayed Toronto S.E. 09:53:03 2024-04-30 am EDT 5-day change 1st Jan Change
0.015 CAD -.--% Intraday chart for Aequus Pharmaceuticals Inc. -.--% -40.00%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Aequus Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Aequus Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Aequus Says Zimed PF Now Available in Canada MT
Aequus Pharmaceuticals Inc. Announces Launch of Zimed PF in Canada CI
Aequus Pharmaceuticals Announces Zimed PF Website Launch MT
Aequus Pharmaceuticals Pauses Sales Of Evolve Intensive Eyedrops, Gel in Canada MT
Aequus Pharmaceuticals Inc. Announces Pause in Sales of Evolve Intensive Eyedrop and Intensive Gel Products in Canada CI
Aequus Pharmaceuticals Announcds Financing to Support Launch of Zimed Preservative Free MT
Aequus Pharmaceuticals Inc. Increases Its Debt by $400,000 to Support the Launch of Zimed Pf CI
Aequus Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Aequus Pharmaceuticals Inc. Auditor Raises 'Going Concern' Doubt CI
Aequus Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Aequus Pharmaceuticals Inc. Announces the Resignation of Stuart Fowler from the Board of Directors CI
Aequus Announces Health Canada Notice of Compliance for Zimed® Preservative Free (Bimatoprost 0.03%) CI
Aequus Announces Sandoz Contract Expiry at Year End and Expected Health Canada Approval for Zimed PF MT
Aequus Pharmaceuticals Inc. Expects Health Canada Approval for Zimed® PF (Preservative Free) CI
Aequus Pharmaceuticals Inc. Agrees to End Its Promotional Service Agreement with Sandoz Canada Inc CI
Aequus Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Aequus Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Aequus Pharmaceuticals Chairman and CEO Doug Janzen Increases Ownership Interest MT
Aequus Signs Distribution Agreement with SCOPE Ophthalmics for Canadian Distribution Rights of Dry Eye Products MT
Aequus Pharmaceuticals Inc. Signs Exclusive Distribution Agreement with SCOPE Ophthalmics for Canadian Distribution Rights of Dry Eye Products CI
Aequus Pharmaceuticals Reports FY 2021, Q1 2022, Financial Results MT
Aequus Pharmaceuticals Inc. Auditor Raises 'Going Concern' Doubt CI
Aequus Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Chart Aequus Pharmaceuticals Inc.
More charts
Aequus Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company focused on developing, advancing, and promoting differentiated products. The Company is engaged in the sale and marketing of several commercial products in ophthalmology and transplant. Its pipeline products include Evolve Intensive Gel, Evolve Daily Intensive, SCOPE Portfolio, Zimed PF and REV-0100 / ReVision. Evolve Intensive Gel and Evolve Daily Intensive contains lubricating eye drops intended for use in the relief of discomfort that arises from dry eye sensations, including dryness, soreness, feelings of grit, and irritation. Zimed PF is a preservative-free multi-dose Bimatoprost for glaucoma patients in Canada. REV-0100 is in preclinical development as a treatment for Stargardt disease. It plans to build on its Canadian commercial platform through the launch of additional products that are either created internally or brought in through an acquisition or license.
More about the company
  1. Stock Market
  2. Equities
  3. AQS Stock
  4. News Aequus Pharmaceuticals Inc.
  5. Aequus Pharmaceuticals Announces Zimed PF Website Launch